Handok, Genexine to join forces in co-development of new drugs

Published: 2012-02-07 06:57:00

Updated: 2012-02-07 06:57:00

Handok Pharmaceutical and Genexine Co., a drug development biotech, agreed to join hands to develop biobetters and biodrugs so that they can stay competitive with its foreign rivals.

The two companies signed a memorandum of understanding on Thursday to develop and commercialize the sustained-r...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK